Answers are grounded in this paper and cite their sources.
Patient-reported outcome (PRO) and quality of life (QoL) assessments for multiple myeloma (MM) patients are traditionally collected at infrequent intervals using burdensome instruments, resulting in limited clinical visibility between visits. This creates a critical gap in care, as evolving symptoms and treatment-related toxicities frequently occur outside scheduled encounters and may remain unrecognized. A single-centre pilot study evaluated the feasibility and clinical utility of a short message service (SMS)-based remote monitoring platform, assessing 8 symptoms and 10 QoL domains for 58 MM patients over 90 days. End-points included feasibility and engagement measured using completion rates, time burden and identification of clinically actionable events. A total of 1604 assessments were delivered, with an overall completion rate of 85.5%, and 72.4% of participants achieving >80% completion rate. Median completion time was 1.80 min. During the 90-day study period, 215 predefined alerts were generated, of which 101 (47.0%) prompted clinical intervention within 48 h, frequently occurring outside routine clinic visits. SMS-based remote monitoring demonstrated high feasibility, sustained engagement and minimal patient burden. This platform enabled real-time identification of symptoms and facilitated rapid follow-up by clinicians, supporting its potential for remote therapeutic monitoring rather than a passive data collection tool.
No takes yet. Share an insight, caveat, or question.
Tellez et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: